Paracrine IL-2 Is Required for Optimal Type 2 Effector Cytokine Production
dc.contributor.author | Olson, Matthew R. | |
dc.contributor.author | Ulrich, Benjamin J. | |
dc.contributor.author | Hummel, Sarah A. | |
dc.contributor.author | Khan, Ibrahim | |
dc.contributor.author | Meuris, Brice | |
dc.contributor.author | Cherukur, Yesesri | |
dc.contributor.author | Dent, Alexander L. | |
dc.contributor.author | Janga, Sarath Chandra | |
dc.contributor.author | Kaplan, Mark H. | |
dc.contributor.department | Pediatrics, School of Medicine | en_US |
dc.date.accessioned | 2019-02-18T14:46:26Z | |
dc.date.available | 2019-02-18T14:46:26Z | |
dc.date.issued | 2017-06-01 | |
dc.description.abstract | IL-2 is a pleiotropic cytokine that promotes the differentiation of Th cell subsets, including Th1, Th2, and Th9 cells, but it impairs the development of Th17 and T follicular helper cells. Although IL-2 is produced by all polarized Th subsets to some level, how it impacts cytokine production when effector T cells are restimulated is unknown. We show in this article that Golgi transport inhibitors (GTIs) blocked IL-9 production. Mechanistically, GTIs blocked secretion of IL-2 that normally feeds back in a paracrine manner to promote STAT5 activation and IL-9 production. IL-2 feedback had no effect on Th1- or Th17-signature cytokine production, but it promoted Th2- and Th9-associated cytokine expression. These data suggest that the use of GTIs results in an underestimation of the presence of type 2 cytokine-secreting cells and highlight IL-2 as a critical component in optimal cytokine production by Th2 and Th9 cells in vitro and in vivo. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Olson, M. R., Ulrich, B. J., Hummel, S. A., Khan, I., Meuris, B., Cherukuri, Y., Dent, A. L., Janga, S. C., … Kaplan, M. H. (2017). Paracrine IL-2 Is Required for Optimal Type 2 Effector Cytokine Production. Journal of immunology (Baltimore, Md. : 1950), 198(11), 4352-4359. | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/18417 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Association of Immunologists | en_US |
dc.relation.isversionof | 10.4049/jimmunol.1601792 | en_US |
dc.relation.journal | Journal of Immunology | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Brefeldin A | en_US |
dc.subject | Cell Differentiation | en_US |
dc.subject | Cytokines | en_US |
dc.subject | Interleukin-2 | en_US |
dc.subject | Interleukin-9 | en_US |
dc.subject | Lymphocyte Activation | en_US |
dc.subject | Mice, Inbred C57BL | en_US |
dc.subject | Monensin | en_US |
dc.subject | Paracrine Communication | en_US |
dc.subject | Protein Synthesis Inhibitors | en_US |
dc.subject | Proton Ionophores | en_US |
dc.subject | STAT5 Transcription Factor | en_US |
dc.subject | Th1 Cells | en_US |
dc.subject | Th17 Cells | en_US |
dc.subject | Th2 Cells | en_US |
dc.title | Paracrine IL-2 Is Required for Optimal Type 2 Effector Cytokine Production | en_US |
dc.type | Article | en_US |